profiles

Exclusive By Nicholas Florko and Matthew Herper

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

Health By Andrew Joseph

‘We didn’t follow through’: He wrote the Ebola ‘lessons learned’ report for Obama. Now he weighs in on coronavirus response

Health By Andrew Joseph

After 40 years, the Alzheimer’s Association sees signs of progress against a devastating disease. Is it real?

Politics By STAT staff

Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation

Health Tech By Megan Thielking

A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation

Biotech By Nicholas Florko

The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025

Biotech By Nicholas Florko

The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism

Pharma By Eric Boodman

First it was aspirin, then Xarelto. What’s Bayer’s next big thing?

Politics By Nicholas Florko

BIO’s new board chair on the industry’s bad reputation: ‘That’s ridiculous’

Politics By Lev Facher and Nicholas Florko

Frontrunner to lead FDA, dogged by controversies, has developed knack for confronting them

Health Tech By Casey Ross

How an AI expert took on his toughest project ever: writing code to save his son’s life

Politics By Lev Facher

Former pharma hawk McCaskill: Drug pricing system is a ‘stinking stew of a mess’

Health By Megan Thielking

Health tech companies often flop. But this researcher’s track record suggests there’s a strategy for success

Biotech By Kate Sheridan

BIO’s new board chair on drug pricing, diversity, and going off-script

Health By Andrew Joseph

The chronic-pain quandary: Amid a reckoning over opioids, a doctor crusades for caution in cutting back

Health By Megan Thielking

‘This is the tip of the iceberg’: More than 8,500 women have joined the 500 Women Scientists database

Politics By Lev Facher

‘He calls me, I call him’: Alex Azar on his relationship with President Trump, drug pricing, and winning over skeptical conservatives

Politics By Damian Garde and Nicholas Florko

The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress

Politics By Lev Facher

An ambassador to the Vatican. A GOP megadonor. And now, a rare Republican joining Democrats to take on pharma

Heavyweights By Sharon Begley

‘I really don’t know what happened to Jim’: Friends ask where James Watson’s odious attitudes about race came from

In the Lab By Andrew Joseph, Rebecca Robbins, and Sharon Begley

An outsider claimed to make genome-editing history — and the world snapped to attention

In the Lab By Eric Boodman

How the Navy brought a once-derided scientist out of retirement — and into the virus-selling business

Lessons Learned By Kate Sheridan

Lessons Learned: Here’s why this Broad Institute exec is jumping to a biotech startup

Lessons Learned By Kate Sheridan

Lessons Learned: How to engineer a data science career

Politics By Nicholas Florko

With PBMs firmly in Washington’s crosshairs, their top lobbyist steps down with no regrets